Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol—EASE
Steven M. Grunberg(University of Bonn), Jørn Herrstedt(Zealand University Hospital), Judith A. Boice(Alexion Pharmaceuticals (United States)), José Dinis(Instituto Português de Oncologia Francisco Gentil), Elizabeth Beckford(Merck & Co., Inc., Rahway, NJ, USA (United States)), Anish Maru(Merck & Co., Inc., Rahway, NJ, USA (United States)), James S. Hardwick(United States Military Academy), Alexandra D. Carides(Merck & Co., Inc., Rahway, NJ, USA (United States)), Daniel T. T. Chua(Chinese University of Hong Kong), Suzanne DeVandry(Merck & Co., Inc., Rahway, NJ, USA (United States)), Arlene Taylor(Merck & Co., Inc., Rahway, NJ, USA (United States)), Fausto Roila(Santa Maria Nuova Hospital)
Cited by 221
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines
|Annals of Oncology|2012|854
American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006
|Journal of Clinical Oncology|2006|743
Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines
|Journal of Clinical Oncology|1999|670